Faculty profile

Hans Chung

Back to faculty

Associate ProfessorDepartment of Radiation OncologyUniversity of Toronto

Hans Chung

Associate Professor

Department of Radiation Oncology

Temerty Faculty of Medicine

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
15 publications in the last five years, latest in 2027.
Last author on 1 recent paper. In many fields the last author leads the lab.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students. How applying works · What these words mean

Academic metrics

Publications

980

Citations

Collaborators

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them. What is the h-index?

Profiles and links

University Profile

Search on Google Scholar

Search on ResearchGate

OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Toronto profile.

Latest papers

Prostate and pelvic SABR with or without a focal boost: results from a multicenter phase II prospective clinical trial.
Clinical and translational radiation oncology · 2027
SBRT vs HDR Brachytherapy for Intermediate-Risk Prostate Cancer.
JAMA network open · 2026
Bowel Bag Dosimetric Parameters for Ultrahypofractionated Pelvic Elective Nodal Irradiation in Prostate Cancer.
International journal of radiation oncology, biology, physics · 2026

All 47 publications

47 publications.

Prostate and pelvic SABR with or without a focal boost: results from a multicenter phase II prospective clinical trial.

Alayed Y, Gopaul D, Mendez LC, Kwan W, Liu SK, Chu W, Tseng CL, Cheung P, Vesprini D, Chung H, Morton G, Correa R, Musunuru B, Davidson M, Ravi A, Deabreu A, Mamedov A, Poon E, Zhang L, Loblaw A

Clinical and translational radiation oncology2027

DOI: 10.1016/j.ctro.2026.101256 PMID: 42750816

SBRT vs HDR Brachytherapy for Intermediate-Risk Prostate Cancer.

Udovicich C, Cheung P, Chu W, Chung H, Detsky J, Liu S, Morton G, Tseng CL, Vesprini D, Hudson JM, Ong WL, Kennedy T, Helou J, Davidson M, Ravi A, McGuffin M, Zhang L, Mamedov A, Deabreu A, Kulasingham-Poon M, Loblaw A

JAMA network open20262 citationsOpen Access

DOI: 10.1001/jamanetworkopen.2026.0146 PMID: 41739470

Bowel Bag Dosimetric Parameters for Ultrahypofractionated Pelvic Elective Nodal Irradiation in Prostate Cancer.

Ong WL, Davidson M, Wronski M, Kang T, Cheung P, Chu W, Chung H, Liu S, Morton G, Tseng CL, Vesprini D, Zhang L, Poon C, Loblaw A

International journal of radiation oncology, biology, physics2026

DOI: 10.1016/j.ijrobp.2025.08.014 PMID: 40819809

Time toxicity in patients receiving brachytherapy and hormonal therapy for recurrent prostate cancer: a cohort study.

Chow R, Bayrakdarian S, Zimmermann C, Richards GC, Heneghan C, Leigh J, Chung H

BMJ supportive & palliative care2026Senior author

DOI: 10.1136/spcare-2026-006361 PMID: 42601182

Comparison of the EORTC QLQ PR25 and the FACT-P for assessing quality of life in patients with prostate cancer - an updated literature review.

Chen D, Jomy J, Ning T, Cheng S, Khan M, Bottomley A, Cella D, Chung H, Lee SF, Emmenegger U, Hird A, Chow E, Wong HCY, Raman S

Current opinion in supportive and palliative care2026

DOI: 10.1097/spc.0000000000000786 PMID: 41610033

Time toxicity in health research: a cross-sectional analysis.

Serran M, Zhang D, Xiao KY, Chung H, Leigh J, Chow R

BMJ supportive & palliative care2026

DOI: 10.1136/spcare-2026-006145 PMID: 41698803

Two-fraction Versus Five-fraction Stereotactic Body Radiotherapy for Intermediate-risk Prostate Cancer: The TOFFEE Meta-analysis of Individual Patient Data from Four Prospective Trials.

Udovicich C, Cheung P, Chu W, Chung H, Detsky J, Liu S, Morton G, Szumacher E, Tseng CL, Vesprini D, Ong WL, Kennedy T, Davidson M, Ravi A, McGuffin M, Zhang L, Mamedov A, Deabreu A, Kulasingham-Poon M, Loblaw A

European urology oncology20259 citationsOpen Access

DOI: 10.1016/j.euo.2024.12.015 PMID: 39904690

Every Other Day or Once a Week: Long-term Oncological Outcomes in the Phase 2 PATRIOT Trial of Prostate Stereotactic Ablative Body Radiotherapy.

Ong WL, Quon H, Ong A, Cheung P, Chu W, Chung H, Vesprini D, Chowdhury A, Panjwani D, Alayed Y, Pang G, Korol R, Davidson M, Ravi A, McCurdy B, Zhang L, Kulasingham-Poon M, Mamedov A, Deabreu A, Loblaw A

European urology oncology20253 citationsOpen Access

DOI: 10.1016/j.euo.2025.03.011 PMID: 40288917

Stereotactic Radiation Therapy for Localized Prostate Cancer: 10-Year Outcomes From Three Prospective Trials.

Kennedy TAC, Ong WL, Quon H, Cheung P, Chu W, Chung H, Vesprini D, Panjwani D, Alayed Y, Pang G, Korol R, Zhang L, Mamedov A, Deabreu A, Loblaw A

International journal of radiation oncology, biology, physics2025

DOI: 10.1016/j.ijrobp.2024.09.009 PMID: 39293531

Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion - Results from the 2SMART phase 2 trial.

Ong WL, Cheung P, Chung H, Chu W, Detsky J, Liu S, Morton G, Szumacher E, Tseng CL, Vesprini D, Davidson M, Ravi A, McGuffin M, Zhang L, Mamedov A, Deabreu A, Kulasingham-Poon M, Loblaw A

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology202331 citations

DOI: 10.1016/j.radonc.2023.109503 PMID: 36754232

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Hans Chung

Research

Latest papers

Prostate and pelvic SABR with or without a focal boost: results from a multicenter phase II prospective clinical trial.

SBRT vs HDR Brachytherapy for Intermediate-Risk Prostate Cancer.

Bowel Bag Dosimetric Parameters for Ultrahypofractionated Pelvic Elective Nodal Irradiation in Prostate Cancer.

Time toxicity in patients receiving brachytherapy and hormonal therapy for recurrent prostate cancer: a cohort study.

Comparison of the EORTC QLQ PR25 and the FACT-P for assessing quality of life in patients with prostate cancer - an updated literature review.

Time toxicity in health research: a cross-sectional analysis.

Two-fraction Versus Five-fraction Stereotactic Body Radiotherapy for Intermediate-risk Prostate Cancer: The TOFFEE Meta-analysis of Individual Patient Data from Four Prospective Trials.

Every Other Day or Once a Week: Long-term Oncological Outcomes in the Phase 2 PATRIOT Trial of Prostate Stereotactic Ablative Body Radiotherapy.

Stereotactic Radiation Therapy for Localized Prostate Cancer: 10-Year Outcomes From Three Prospective Trials.

Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion - Results from the 2SMART phase 2 trial.

Frequent collaborators

Andrew Loblaw

Patrick Cheung

William Chu

Gerard Morton

Danny Vesprini

Edward Chow

Chia-Lin Tseng

Stanley Liu

Ewa Szumacher

Darby Erler

Carlo DeAngelis

Hany Soliman

Laura D'Alimonte

Ian Poon

Arjun Sahgal

Shun Wong

Jay Detsky

Merrylee McGuffin

May Tsao

Elizabeth Barnes

Lee Chin

Drew Brotherston

Geordi Pang

Renee Korol

Linda Probyn

Moti Paudel

Marko Popovic

Jennifer Leigh

Boyd McCurdy

Erin Wong

Joel Rubenstein

Chirag Patel

Laurence Klotz

Natalie Coburn

Camilla Zimmermann

Gregory Pond

Julie Hallet

Simron Singh

Douglas Loblaw

Urban Emmenegger